|
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical research trials and Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes  Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
For Condition: Diabetes Mellitus, Insulin-Dependent
Status: Completed
Sponsor(s): Procter & Gamble Pharmaceuticals ,
Synopsis: Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: - Age 18-65 - fasting C-peptide <0.3 ng/ml. - HbA1c <10% - Otherwise healthy
Total Enrollment:
Location and Contact Information:
Clinical Research Institute of Southern Oregon
Medforo, Oregon, 97504
United States
Radiant Research
Irvine, California, 92618
United States
Mercury Street Medical
Butte, Montana, 59701
United States
MedStar Clinical Research Center
Washington D.C., District of Columbia, 20003
United States
DGD Research Associates
San Antonio, Texas, 78229
United States
VA Hospital UCSD
San Diego, California, 92161
United States
University of Texas Health Science Center - Texas Diabetes Institute
San Antonio, Texas, 78207
United States
Diablo Clinical Research
Walnut Creek, California, 94598
United States
UNC Diabetes Care Center
Durham, North Carolina, 27713
United States
Springfield Diabetes and Endocrine Center
Springfield, Illinois, 62704
United States
Additional Information:
Study ID Numbers: 2003068;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071409
Other Diabetes Mellitus, Insulin-Dependent Studies:
1. Continuous Glucose Monitors for Children With Diabetes Mellitus
2. Continuous Glucose Monitoring in Children With Type 1 Diabetes Mellitus
3. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
4. Islet Cell Transplants for Diabetes
5. Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Related Studies:
Other Diabetes Mellitus, Insulin-Dependent Clinical Trials
Other Oregon Clinical Trials
Other Medforo Clinical Trials
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
|
|
|
|
|
|
|
|
